Chapter 9 · Biotechnology and Its Applications

9.2 Biotechnology and its Applications

What the tools of recombinant DNA technology are used for: human insulin and recombinant vaccines, gene therapy, stem cells and molecular diagnosis; Bt crops and RNA interference; transgenic animals; and the biosafety, patent and biopiracy questions they raise.

In 1990 a four-year-old girl in the United States was born without a working copy of one gene — the gene for the enzyme adenosine deaminase. Without that enzyme her immune system could not work, and every infection was dangerous. Doctors took some of her white blood cells, gave them a working copy of the gene, grew them in the laboratory and put them back into her blood. She became the first person to receive gene therapy. In the same decade, farmers in several countries began sowing cotton that poisons the caterpillars that bore into its bolls, and a cow in the United States gave milk enriched with a human protein.

All of these rest on the tools of Section 9.1 — restriction enzymes, vectors, competent hosts, PCR and bioreactors. This section is about what they are for: in medicine (human insulin, recombinant vaccines, gene therapy, stem cells and molecular diagnosis), in agriculture (genetically modified crops, Bt cotton and pest resistance by RNA interference), in animals (transgenic mice, cows and others), and finally the rules a society needs once it can change genes — biosafety, patents and biopiracy. NEET questions on this section are mostly about exact facts (which gene, which pest, which year, which enzyme), so the page marks each one clearly.

Biotechnology in Medicine I — Human Insulin and Recombinant Vaccines

Before recombinant DNA, a protein drug had to be extracted from wherever nature made it: insulin from the pancreas of slaughtered animals, growth hormone from human pituitary glands taken after death, a vaccine from the pathogen itself. Every source was limited, and some were risky. Recombinant DNA technology changed the question from "where can we find this protein?" to "which cell shall we ask to make it?".

📘 Definition 9.14 — Recombinant therapeutics

Recombinant therapeutics are drugs (usually proteins) made by organisms that carry the human or pathogen gene for them — that is, made by recombinant DNA technology. Because the protein is the human one, or exactly the antigen needed, it does not set off the unwanted immunological responses seen with similar products isolated from non-human sources, and it can be produced safely, in bulk and with consistent quality.

The figures NEET uses come from the time the syllabus was framed: about 30 recombinant therapeutics had been approved for human use worldwide, and 12 of them were being marketed in India. (Today there are hundreds — insulin, growth hormone, blood-clotting factors, interferons, erythropoietin, monoclonal antibodies — but in an exam the answer is 30 and 12.)

📐 Key fact 9.7 — Insulin: two chains, three bridges, and a peptide that is thrown away
  • Mature insulin is made of two short polypeptide chains: chain A (21 amino acids) and chain B (30 amino acids), held together by disulphide bridges (two between the chains and one within chain A).
  • In mammals, including humans, insulin is synthesised as a prohormone — proinsulin, a single chain with an extra stretch called the C peptide joining the end of chain B to the start of chain A. (Like a pro-enzyme, a prohormone has to be processed before it becomes fully mature and functional.)
  • The C peptide is not present in mature insulin: it is removed during maturation, inside the secretory vesicles of the β-cells of the islets of Langerhans.
  • For decades the insulin used to treat diabetes was extracted from the pancreas of slaughtered cattle and pigs. Animal insulin differs slightly from human insulin, and some patients developed allergy or other reactions to the foreign protein.
📐 Key fact 9.8 — Making human insulin by recombinant DNA (1983)

The main challenge was getting insulin assembled into its mature form. In 1983 the American company Eli Lilly solved it like this:

  1. Two DNA sequences were prepared, one corresponding to chain A and one to chain B of human insulin.
  2. They were introduced into plasmids of E. coli (separately), and the bacteria produced the two insulin chains.
  3. Chains A and B were produced separately, extracted, and combined by creating disulphide bonds to form human insulin.

The product is called Humulin. It is the human hormone itself, so it avoids the allergic reactions caused by animal insulin, and its supply no longer depends on slaughterhouses.

✏️ Example 1 — Two chains, three bridges
(a) How many amino acids does one molecule of mature human insulin contain? (b) How many disulphide bridges does it have, and how many of them link chain A to chain B? (c) A student proposes putting the gene for proinsulin into E. coli and collecting mature insulin from the culture. Why would this not give mature insulin? How did the 1983 method get round the problem? (d) Give two reasons why genetically engineered human insulin is preferred to insulin from pigs.
Find (a), the number of amino acids, before you open the solution:
(a) Chain A has 21 and chain B has 30 amino acids: $21+30=51$. The C peptide is cut out during maturation, so it is not counted.
(b) Three disulphide bridges: two between chains A and B, one within chain A.
(c) E. coli would make proinsulin, a single chain still carrying the C peptide; a bacterium has no enzymes for removing the C peptide, a step that happens in the β-cells of the human pancreas. The 1983 method skipped the problem: it made chain A and chain B separately in E. coli, purified them and joined them by forming disulphide bonds.
(d) It is identical to the human hormone, so it causes no allergic or immune reactions to a foreign protein; and it can be made in unlimited, consistent amounts in bioreactors, without depending on animal pancreases.

In the lab below, choose E. coli, 1983 and step to the point where the bacteria have finished making protein. How many disulphide bridges does the protein in each culture have at that stage?

Choose E. coli, 1983 and press Next step ▸ to step 4 of 7 ("chains made in two cultures"): the readouts show chains present: A (culture 1) · B (culture 2), separate and disulphide bridges: 0. One culture makes only chain A and the other only chain B, so no bridges between chains can form inside a cell. The bridges appear at step 6, when the purified chains are combined chemically (readout 3). Switch to pancreas β-cell: there the bridges form in proinsulin before the C peptide is removed.
Interactive 1 — Making Human Insulin: Pancreas or E. coli?

Choose a route and press Next step ▸ (or ▶ Play). The strip at the top shows the whole process with the current step highlighted; the panel below draws what exists at that step (red dots = chain A, blue = chain B, grey = C peptide, amber = disulphide bridges). Compare how the human β-cell and the 1983 bacterial method reach the same two-chain hormone.

step—
where—
chains present—
disulphide bridges—

Insulin shows how to make a drug; the same logic makes a vaccine. A vaccine has to show the immune system the antigen of a pathogen (Section 8.1) — and an antigen is usually a protein, coded by a gene.

📘 Definition 9.15 — Recombinant vaccines

Recombinant DNA technology allows the antigenic polypeptides of a pathogen to be produced in bacteria or yeast. A vaccine made of such a protein is a recombinant (subunit) vaccine: it contains one antigen, not the whole pathogen, so it cannot cause the disease, and it can be made on a large scale, safely and cheaply.

  • Hepatitis B vaccine — the gene for the surface antigen of the hepatitis B virus (HBsAg) is put into yeast (Saccharomyces cerevisiae). The yeast is grown in bioreactors, the antigen is extracted and purified (downstream processing) and formulated as the vaccine. It was the first recombinant vaccine for human use and is given to newborns in India's immunisation programme.
  • DNA vaccines — instead of the antigen protein, the gene for it (carried in a plasmid) is injected; the person's own cells make the antigen and the immune system responds to it.

Production steps follow Key fact 9.5 of Section 9.1: isolate the antigen gene → ligate it into a vector → transform the host (yeast) → culture in a bioreactor → extract and purify the antigen → formulate, test for quality and safety.

✏️ Example 2 — A vaccine from yeast
(a) Arrange these steps in making a hepatitis B vaccine: (i) yeast cells grown in a stirred-tank bioreactor; (ii) the HBsAg gene ligated into a yeast vector; (iii) purified antigen formulated with a preservative and tested; (iv) yeast cells transformed with the recombinant vector; (v) yeast cells broken open and the antigen purified. (b) Why can a person vaccinated with it not catch hepatitis B from the vaccine? (c) What does the person's immune system make in response? (d) How does a DNA vaccine differ?
(a) ii → iv → i → v → iii: make the recombinant vector, transform the host, culture it at large scale, then downstream processing (purify), formulation and quality control.
(b) The vaccine contains only a surface protein of the virus, made by yeast. There is no viral genome in it, so nothing in it can multiply and cause infection.
(c) Antibodies against HBsAg (and memory B and T cells), so a later infection by the real virus meets a quick, strong secondary response.
(d) A DNA vaccine injects the gene for the antigen, not the antigen; the vaccinated person's own cells make the protein that the immune system then responds to.

In the 1983 method of making human insulin, what was introduced into E. coli?

Biotechnology in Medicine II — Gene Therapy, Stem Cells and Molecular Diagnosis

Insulin injections replace a missing product every day for life. Gene therapy asks a bolder question: could we replace the faulty gene instead? And molecular diagnosis asks: could we see a disease in its genes and proteins before it shows any symptom?

📘 Definition 9.16 — Gene therapy

Gene therapy is a collection of methods that allows the correction of a gene defect diagnosed in a child or an embryo. Genes are inserted into a person's cells and tissues to treat a disease: a normal gene is delivered into the individual or embryo to take over the function of, and compensate for, the non-functional gene.

If only body (somatic) cells such as blood cells are corrected, the change helps the patient but is not inherited. If the gene could be introduced into cells at an early embryonic stage, the correction would be permanent.

📐 Key fact 9.9 — The first clinical gene therapy: ADA deficiency (1990)
  • Given in 1990 to a four-year-old girl with adenosine deaminase (ADA) deficiency.
  • ADA is an enzyme crucial for the immune system to function. The disorder is caused by the deletion of the gene for ADA.
  • Earlier treatments: in some children, bone marrow transplantation; in others, enzyme replacement therapy (functional ADA given by injection). Neither is completely curative.
  • Gene therapy: lymphocytes from the patient's blood are grown in a culture outside the body; a functional ADA cDNA is introduced into them using a retroviral vector; the cells are then returned to the patient.
  • Lymphocytes are not immortal, so the patient needs periodic infusions of genetically engineered lymphocytes. If the ADA gene isolated from marrow cells were introduced into cells at early embryonic stages, it could be a permanent cure.
✏️ Example 3 — Reading the ADA case
(a) Name the enzyme missing in the first patient treated by gene therapy, and the change in her DNA that caused it. (b) Which cells were modified, and with which kind of vector? (c) Why did she need repeated treatments? (d) Enzyme replacement therapy also supplies ADA. Why is it not a cure? (e) Which cells would have to be corrected for a permanent cure?
(a) Adenosine deaminase (ADA), needed for the immune system to function; the gene for ADA had been deleted.
(b) Her lymphocytes, grown in culture outside the body; a functional ADA cDNA was introduced with a (disarmed) retroviral vector.
(c) Lymphocytes are not immortal — they die after a time, and new lymphocytes formed from her own marrow still lack the gene — so periodic infusions of engineered lymphocytes are needed.
(d) Injected enzyme is broken down and must be given again and again; it does not correct the gene, so the cells still cannot make ADA themselves.
(e) Cells that keep dividing and give rise to the blood cells — marrow cells producing ADA — introduced at an early embryonic stage; then every cell descended from them would carry the gene.

The ADA case points to the cells that make a cure permanent: cells that keep dividing for life and give rise to other cells. These are stem cells, and growing and using them is one of the fastest-growing parts of medicine.

📘 Definition 9.17 — Stem cells and stem cell technology

A stem cell is an undifferentiated cell that can (i) renew itself — divide to make more stem cells — and (ii) differentiate into specialised cells. Stem cells are classified by how many kinds of cell they can form (their potency):

PotencyCan formExample
Totipotentevery cell of the body and the extra-embryonic tissues (placenta)the zygote and the cells of its first few divisions
Pluripotentall cell types of the body, but not a whole organismembryonic stem cells from the inner cell mass of the blastocyst
Multipotentseveral related cell typesadult stem cells, e.g. haematopoietic stem cells of the bone marrow (all blood cells); stem cells of umbilical cord blood
Unipotentone cell typemuscle satellite cells (muscle fibres)

Stem cell technology is the isolation, culture and use of stem cells to repair or replace damaged cells and tissues (regenerative medicine). Established uses: bone marrow (haematopoietic stem cell) transplantation for leukaemia, thalassaemia and immune deficiencies such as ADA deficiency; umbilical cord blood banking; growing skin for burn patients and corneal stem cells to restore sight. Under research: repairing heart muscle, nerve cells and pancreatic β-cells. A newer source is induced pluripotent stem (iPS) cells — adult cells reprogrammed, by adding a few genes, to behave like embryonic stem cells. Using embryonic stem cells raises an ethical issue, because an early embryo is destroyed to obtain them.

Medicine depends on finding a disease early. Conventional methods — analysis of serum and urine — can detect an infection only once the pathogen has multiplied enough, often after symptoms appear. Recombinant DNA technology, PCR and ELISA can detect it far earlier.

📘 Definition 9.18 — Molecular diagnosis
  • PCR amplifies the nucleic acid of a pathogen, so a very low concentration of a bacterium or virus can be detected — at a time when the symptoms of the disease are not yet visible. It is routinely used to detect HIV in suspected AIDS patients, to detect mutations in genes in suspected cancer patients, and to identify many other genetic disorders.
  • Probe and autoradiography. A single-stranded DNA or RNA tagged with a radioactive molecule (a probe) is allowed to hybridise to its complementary DNA in a clone of cells, followed by detection using autoradiography. The clone having a mutated gene will not appear on the photographic film, because the probe is not complementary to the mutated gene.
  • ELISA (enzyme-linked immunosorbent assay) is based on the principle of antigen–antibody interaction. Infection by a pathogen can be detected by the presence of its antigens (proteins, glycoproteins, etc.) or by detecting the antibodies synthesised against the pathogen.
MethodDetectsPrincipleTypical use
Serum / urine analysisproducts of an established infectionconventional biochemistry, microscopyafter symptoms appear
PCRpathogen's DNA or RNA; mutated genesamplification of a target nucleic acid ($2^{n}$ copies)HIV, cancer mutations, genetic disorders — very early
Probe + autoradiographypresence or absence of a particular sequencehybridisation of a labelled complementary strandpicking out a clone with a mutated gene
ELISApathogen's antigens, or antibodies against itantigen–antibody binding, revealed by an enzyme's coloured productHIV screening, many infections
✏️ Example 4 — Choosing the test
Which method — PCR, probe hybridisation or ELISA — best fits each case, and why? (a) A blood bank wants a cheap test to screen thousands of donations for antibodies against HIV. (b) A health worker was exposed to HIV four days ago; antibodies take weeks to appear, but the hospital wants to know as early as possible whether the virus is present. (c) A laboratory has 500 bacterial clones of a human gene and needs to find the clone carrying a mutated copy. (d) A baby is born to an HIV-positive mother. The mother's antibodies cross the placenta, so the baby's blood has anti-HIV antibodies whether or not the baby is infected.
(a) ELISA: it detects antibodies by antigen–antibody interaction, is cheap and handles many samples.
(b) PCR: it detects the viral nucleic acid itself, amplifying even a very low concentration, before the body has made antibodies.
(c) Probe hybridisation with autoradiography: a radioactive probe complementary to the normal sequence binds every clone except the mutated one, which does not appear on the film.
(d) PCR: an antibody test would be positive because of the mother's antibodies, so only detecting the virus's own nucleic acid tells whether the baby is infected.

In the first clinical gene therapy (1990), how was the functional ADA gene delivered?

Biotechnology in Agriculture — GM Crops, Bt Toxin and RNA Interference

There are three options for increasing food production: agro-chemical-based agriculture, organic agriculture and genetically engineered crop-based agriculture. The Green Revolution succeeded in tripling the food supply, but it was still not enough for a growing population. Its higher yields came partly from improved crop varieties, but mainly from better management and the use of agrochemicals — fertilisers and pesticides — which are often too expensive for farmers in the developing world, and which harm the environment. Further increases in yield from the existing varieties are not possible by conventional breeding. Genetically modified crops offer a way to grow more while using fewer chemicals.

📘 Definition 9.19 — Genetically modified organisms (GMOs)

Plants, bacteria, fungi and animals whose genes have been altered by manipulation are called genetically modified organisms (GMOs). An organism that carries and expresses a gene from another species is transgenic; the gene is a transgene. Plant genes are usually changed with the Ti-plasmid vector of Agrobacterium tumefaciens or by biolistics (Section 9.1).

📐 Key fact 9.10 — What genetic modification has done for crop plants
  1. made crops more tolerant to abiotic stresses — cold, drought, salt, heat;
  2. reduced reliance on chemical pesticides (pest-resistant crops);
  3. helped to reduce post-harvest losses (e.g. tomatoes whose ripening is delayed, so they stay firm longer);
  4. increased the efficiency of mineral usage by plants — this prevents early exhaustion of the fertility of the soil;
  5. enhanced the nutritional value of food — e.g. Golden rice, a vitamin A-enriched rice (its grains make β-carotene, the precursor of vitamin A, which gives them their golden colour).

GM has also been used to create tailor-made plants that supply alternative resources to industries — starches, fuels and pharmaceuticals.

The best-known application is pest resistance. A pest-resistant crop makes its own protection, so the farmer sprays less insecticide. NEET concentrates on two ways of achieving it: a bacterial toxin gene (Bt crops) and RNA interference.

📘 Definition 9.20 — Bt toxin and the cry genes

Bt toxin is produced by the soil bacterium Bacillus thuringiensis ("Bt" for short). Some strains of B. thuringiensis produce proteins that kill certain insects — lepidopterans (tobacco budworm, armyworm), coleopterans (beetles) and dipterans (flies, mosquitoes). During a particular phase of its growth the bacterium forms protein crystals that contain the toxic insecticidal protein.

The toxin is coded by a gene named cry; there are many of them, and most Bt toxins are specific to a group of insects, so the gene chosen depends on the crop and the targeted pest:

GeneProteinControls
cryIAc and cryIIAbCryIAc, CryIIAbcotton bollworms
cryIAbCryIAbcorn borer

The Bt toxin gene has been cloned from the bacterium and expressed in plants, giving them resistance to insects without the need for insecticides — in effect the plant makes a bio-pesticide. Examples: Bt cotton, Bt corn, rice, tomato, potato and soybean. (Gene names are written in lower-case italics, cry; the proteins they code for start with a capital, Cry. In Indian texts the numbers are often printed as Roman numerals, cryIAc; in research papers as cry1Ac.) Bt cotton was approved for cultivation in India in 2002 and now covers most of the country's cotton area.

📐 Key fact 9.11 — How Bt toxin kills an insect but not the bacterium
  • In the bacterium (and in the Bt plant) the toxin exists as an inactive protoxin, so it does not harm the cell that makes it.
  • When an insect eats it, the inactive toxin is converted into its active form by the alkaline pH of the insect's gut, which solubilises the crystals.
  • The activated toxin binds to the surface of the midgut epithelial cells and creates pores, which cause cell swelling and lysis and eventually the death of the insect.

Mammals, including humans, are not affected: their stomach is acidic rather than alkaline, the protein is digested like any other, and their gut cells lack the specific receptors to which the activated toxin binds.

Not every pest is an insect. The nematode Meloidogyne incognita infects the roots of tobacco plants and causes a great reduction in yield. It was defeated by switching off one of its own genes — from inside the plant.

📘 Definition 9.21 — RNA interference (RNAi)

RNA interference (RNAi) takes place in all eukaryotic organisms as a method of cellular defence. It involves the silencing of a specific mRNA by a complementary double-stranded RNA (dsRNA) molecule that binds to the mRNA and prevents its translation. The source of the complementary RNA in nature can be an infection by viruses having RNA genomes, or mobile genetic elements (transposons) that replicate via an RNA intermediate.

📐 Key fact 9.12 — Nematode-resistant tobacco by RNAi
  1. Using Agrobacterium vectors, nematode-specific genes were introduced into the host plant (tobacco).
  2. The introduced DNA was arranged so that it produced both sense and anti-sense RNA in the host cells.
  3. These two RNAs, being complementary to each other, formed a double-stranded RNA (dsRNA) that initiated RNAi.
  4. The dsRNA silenced the specific mRNA of the nematode when the nematode fed on the plant: the protein it codes for could not be made.
  5. The parasite could not survive in a transgenic host expressing the specific interfering RNA — the plant was protected.
✏️ Example 5 — Bt cotton and RNAi tobacco
(a) Which cry genes would you put into cotton to protect it from bollworms, and which into maize to protect it from the corn borer? (b) Bacillus thuringiensis makes a protein that kills insects. Why does the bacterium itself survive? (c) A cow is fed the leaves of Bt cotton. Give two reasons why the toxin does not harm it. (d) In the nematode-resistant tobacco, why must the transgene produce both sense and anti-sense RNA? (e) Name the vector used to put the nematode gene into tobacco, and the pest it defeats.
(a) Cotton: cryIAc and cryIIAb (bollworms). Maize: cryIAb (corn borer). Bt toxins are insect-group specific, so the gene is matched to the pest.
(b) The toxin is made as an inactive protoxin in crystals; it becomes active only in the alkaline gut of an insect.
(c) The cow's stomach is not alkaline, so the crystals are not activated and the protein is digested; and its gut cells lack the specific receptors the activated toxin binds to.
(d) RNAi is started by double-stranded RNA. Sense and anti-sense RNA are complementary, so together they pair into dsRNA; either one alone stays single-stranded and starts no silencing.
(e) An Agrobacterium (Ti-plasmid-based) vector; the root-knot nematode Meloidogyne incognita.

In the tracer below, choose RNAi in tobacco and the transgene that makes sense RNA only. Run it to the last stage. What happens to the nematode?

Choose RNAi in tobacco → transgene makes sense RNA only and drag stage to 6: the readouts show dsRNA formed: no, nematode mRNA: translated, outcome: nematode survives, root galls form. Sense RNA has the same sequence as the nematode's mRNA, so it cannot pair with it, and with no anti-sense partner no dsRNA forms. Switch to sense + anti-sense RNA: at stage 3 the readout becomes dsRNA formed: yes and at stage 6 nematode dies.
Interactive 2 — Pest-Resistance Tracer: Bt Toxin and RNAi

Choose a mechanism and a condition, then drag stage (or press ▶ Play) to follow the molecules from the transgene in the plant to the fate of the pest. The stage strip names each step; the readouts track the one condition that decides the outcome — the pH of the gut that eats Bt toxin, or whether double-stranded RNA forms.

1
stage—
deciding condition—
molecule—
outcome—

Why does Bt toxin become active in a bollworm's gut?

Transgenic Animals, Biosafety, Patents and Biopiracy

The same micro-injection and viral vectors that deliver genes into animal cells (Section 9.1) can change a whole animal, if the gene is put into a fertilised egg or an early embryo. Every cell of the resulting animal then carries the new gene, and so do its offspring.

📘 Definition 9.22 — Transgenic animals

Animals whose DNA has been manipulated to possess and express an extra (foreign) gene are called transgenic animals. Transgenic rats, rabbits, pigs, sheep, cows and fish have been produced, but over 95 % of all existing transgenic animals are mice.

📐 Key fact 9.13 — Why transgenic animals are produced
  1. Normal physiology and development — to study how genes are regulated and how they affect the normal functions of the body and its development, e.g. the study of complex factors involved in growth such as insulin-like growth factor. A gene that alters the formation of such a factor is introduced and the effects are watched.
  2. Study of disease — many transgenic animals are designed to understand how genes contribute to the development of disease; they serve as models for human diseases, so new treatments can be investigated. Models exist for cancer, cystic fibrosis, rheumatoid arthritis and Alzheimer's disease.
  3. Biological products — medicines needed to treat some human diseases can be made in animals carrying the gene for the product: e.g. human protein α-1-antitrypsin, used to treat emphysema; similar attempts for treating phenylketonuria (PKU) and cystic fibrosis. In 1997 the first transgenic cow, Rosie, produced human protein-enriched milk (2.4 grams per litre). The milk contained the human alpha-lactalbumin and was nutritionally a more balanced product for human babies than natural cow milk.
  4. Vaccine safety testing — transgenic mice are being developed for use in testing the safety of vaccines before they are used on humans; they are used to test the safety of the polio vaccine. If successful and reliable, they could replace the use of monkeys.
  5. Chemical safety testing (toxicity testing) — the procedure is the same as for testing the toxicity of drugs. Transgenic animals carry genes that make them more sensitive to toxic substances than non-transgenic animals; they are exposed to the substances and the effects studied, so results are obtained in less time.
✏️ Example 6 — Rosie's milk
(a) A transgenic cow like Rosie gives 25 litres of milk a day containing human alpha-lactalbumin at 2.4 g per litre. How many grams of the human protein does she produce per day? (b) Over a lactation of 300 days, how many kilograms is that? (c) Why was this milk described as better for human babies? (d) Which use of transgenic animals in Key fact 9.13 does Rosie illustrate, and which use does a mouse that develops cystic fibrosis illustrate?
Find (a), the grams of human protein per day, before you open the solution:
(a) $25\ \text{L/day}\times2.4\ \text{g/L}=60\ \text{g}$ per day.
(b) $60\ \text{g/day}\times300\ \text{days}=18\,000\ \text{g}=18\ \text{kg}$.
(c) It contained human alpha-lactalbumin, a protein of human milk, so its composition was nutritionally more balanced for human babies than ordinary cow milk.
(d) Rosie: biological products (a human protein made in an animal). The cystic-fibrosis mouse: a model for the study of a human disease.

Changing the genes of organisms and releasing them into fields, foods and medicines raises questions that science alone cannot settle: who checks that a GM organism is safe, and who owns a gene, a variety or the knowledge of a traditional medicine?

📘 Definition 9.23 — Biosafety and the GEAC

The manipulation of living organisms by the human race cannot go on any further without regulation. Introducing a GM organism may have unpredictable results when it enters an ecosystem — for example, the transgene may spread to wild relatives, non-target organisms may be harmed, pests may evolve resistance, or a new protein in food may cause allergy. Biosafety is the set of rules and tests that keep such risks low.

The Indian Government has set up organisations such as the GEAC (Genetic Engineering Approval Committee, renamed the Genetic Engineering Appraisal Committee in 2010), which makes decisions regarding the validity of GM research and the safety of introducing GM organisms for public services. A GM crop such as Bt cotton can be grown commercially in India only after GEAC approval.

📘 Definition 9.24 — Patents, biopatents and biopiracy

A patent is a right granted by a government to an inventor that stops others from commercially using the invention. When patents are granted for biological entities and for products derived from them, they are called biopatents. Companies have applied for patents on products and technologies that make use of genetic materials, plants and other biological resources that have long been identified, developed and used by farmers and indigenous people of a country.

  • India has an estimated 2 lakh varieties of rice, and 27 documented varieties of Basmati are grown in India alone; Basmati is distinct for its unique aroma and flavour. In 1997 an American company got patent rights on Basmati rice through the US Patent and Trademark Office. This allowed it to sell a "new" variety of Basmati in the US and abroad — a variety actually derived from Indian farmers' varieties, crossed with semi-dwarf varieties and claimed as an invention.
  • Other people have tried to patent uses, products and processes based on Indian traditional herbal medicines, e.g. turmeric and neem.

Biopiracy is the term used to refer to the use of bio-resources by multinational companies and other organisations without proper authorisation from the countries and people concerned, without compensatory payment. Industrialised nations are rich financially but poor in biodiversity and traditional knowledge; the developing and under-developed world is rich in both. There is growing realisation of this injustice: some nations are developing laws to prevent unauthorised exploitation of their bio-resources and traditional knowledge. The Indian Parliament has cleared the second amendment of the Indian Patents Bill, which takes such issues into consideration, including patent terms, emergency provisions and research and development initiative; and India's Biological Diversity Act (2002) requires approval and benefit-sharing before its bio-resources are used commercially.

✏️ Example 7 — Biopiracy, biosafety or neither?
Classify each case as biopiracy, a biosafety (GEAC) matter, or neither, and give a reason. (a) A foreign firm crosses an Indian Basmati with a semi-dwarf rice and patents the product as its own new invention, paying nothing to India. (b) A company wants to start field trials of a new GM mustard in Haryana. (c) A firm patents a process using the anti-fungal property of neem leaves, known to Indian villagers for centuries, without permission or payment. (d) An Indian institute signs an agreement with a tribal community for a medicinal plant, obtains government approval and shares the profits with the community.
(a) Biopiracy: the bio-resource (Indian Basmati varieties) is used and patented without authorisation or compensatory payment — the 1997 Basmati case in outline.
(b) Biosafety: releasing a GM organism into the environment needs GEAC approval of the research and its safety.
(c) Biopiracy: traditional knowledge and a bio-resource used and patented without permission or payment (as with neem and turmeric).
(d) Neither: the resource is used with proper authorisation and with benefit-sharing — the opposite of biopiracy.

Which statement about the transgenic cow Rosie is correct?

⚠️ NEET traps — applications of biotechnology

1. Insulin numbers. Chain A 21, chain B 30 amino acids; joined by disulphide bridges. The C peptide is in proinsulin, not in mature insulin. Eli Lilly, 1983: two DNA sequences (A and B) in plasmids of E. coli; chains made separately and then joined.

2. Recombinant therapeutics: about 30 approved worldwide, 12 marketed in India. Hepatitis B vaccine: antigen made in yeast.

3. ADA deficiency. 1990, a four-year-old girl; cause: deletion of the ADA gene; cells treated: lymphocytes; vector: retrovirus; what goes in: functional ADA cDNA. Bone-marrow transplant and enzyme replacement are not completely curative; lymphocytes are not immortal → periodic infusions.

4. Diagnosis. PCR — nucleic acid, very low concentration, before symptoms (HIV, cancer mutations). ELISA — antigen–antibody interaction (antigens or antibodies). In probe hybridisation the mutated clone does not appear on the film.

5. Bt toxin. From Bacillus thuringiensis; inactive protoxin crystals; activated by the alkaline (not acidic) gut pH; binds midgut epithelial cells, makes pores → swelling, lysis. Kills lepidopterans, coleopterans and dipterans.

6. The cry genes. cryIAc and cryIIAb → cotton bollworms; cryIAb → corn borer. Gene in italics and lower case (cry), protein capitalised (Cry).

7. RNAi. Pest: Meloidogyne incognita, a nematode of tobacco roots; vector: Agrobacterium; the transgene makes sense and anti-sense RNA → dsRNA → silences the nematode's mRNA (not the plant's). Natural sources of dsRNA: RNA viruses, transposons with an RNA intermediate.

8. GM crops. Golden rice — vitamin A (β-carotene), not iron. Five benefits: abiotic-stress tolerance, less pesticide, fewer post-harvest losses, better mineral use, nutrition.

9. Transgenic animals. Over 95 % are mice. Rosie, 1997, alpha-lactalbumin, 2.4 g/L. α-1-antitrypsin → emphysema. Transgenic mice test polio vaccine safety.

10. Ethics. GEAC — validity of GM research and safety of release. Basmati patent 1997, American company, US Patent and Trademark Office; 27 documented Basmati varieties in India. Biopiracy = use of bio-resources without authorisation and without compensatory payment.

🚀 Beyond NEET — how insulin and vaccines are made today, and gene editing

Not in the NMC NEET (UG) syllabus; optional background for the curious.

Insulin after 1983. Making two chains and joining them correctly was inefficient. From the late 1980s manufacturers switched to making a single-chain proinsulin (or a shortened precursor) in E. coli or yeast, folding it so the three disulphide bridges form in the right places, and then cutting out the C peptide with enzymes in a tank — copying in a bioreactor what the β-cell does naturally. Modern "insulin analogues" change one or two amino acids so the hormone acts faster or lasts longer.

mRNA vaccines. The COVID-19 vaccines of 2020–21 went one step beyond DNA vaccines: they inject the mRNA for a viral surface protein, wrapped in tiny fat droplets. The person's ribosomes translate it, and the mRNA is soon broken down.

Gene editing. CRISPR–Cas9, a bacterial defence system turned into a tool, cuts DNA at a site chosen by a short guide RNA, so a faulty gene can be repaired in place instead of a normal copy being added. In 2023 the first CRISPR-based treatment, for sickle-cell disease and β-thalassaemia, was approved: the patient's own blood stem cells are edited outside the body and returned — gene therapy and stem cell technology together.

Exercises

I
Recombinant therapeutics, insulin and vaccines.
  • 1 What are recombinant therapeutics? Why are they preferred to similar products isolated from non-human sources? Give the numbers of approved recombinant therapeutics worldwide and in India that NEET uses.
  • 2 Name the two chains of mature insulin, give the number of amino acids in each, and name the bonds that hold them together.
  • 3 What is the C peptide? In which form of insulin is it present, and when is it removed?
  • 4 Describe how human insulin was first produced by recombinant DNA technology: the year, the company, the host, the vector and the way the final hormone was assembled.
  • 5 Why did insulin from cattle and pigs not suit every diabetic patient?
  • 6 A molecule of human proinsulin contains 86 amino acids. How many amino acids are removed when it matures into insulin?
  • 7 For the hepatitis B vaccine, name the antigen, the host organism that makes it, and explain why the vaccine cannot cause hepatitis B.
  • 8 How many of these are made by recombinant DNA technology: human insulin from E. coli; hepatitis B vaccine from yeast; penicillin from Penicillium; insulin extracted from pig pancreas; human growth hormone made in bacteria?
1 Drugs (mostly proteins) produced by recombinant DNA technology, e.g. by microbes carrying the human gene. Being the human protein, they do not cause the unwanted immunological responses of non-human products, and they can be made safely in bulk. About 30 approved worldwide; 12 marketed in India.
2 Chain A (21 amino acids) and chain B (30 amino acids), held together by disulphide bridges (two between the chains; a third lies within chain A).
3 An extra stretch of polypeptide that joins chain B to chain A in proinsulin, the prohormone. It is removed during maturation of insulin in the β-cells; mature insulin lacks it.
4 1983, Eli Lilly (USA). Two DNA sequences, for chains A and B, were introduced into plasmids of E. coli; the chains were produced separately, extracted, and combined by creating disulphide bonds to give human insulin.
5 Animal insulin differs slightly from human insulin, so some patients developed allergies or other reactions to it as a foreign protein; supply also depended on slaughtered animals.
6 Mature insulin has $21+30=51$ amino acids, so $86-51=35$ are removed (the C peptide together with the few linking amino acids at its ends).
7 Hepatitis B surface antigen (HBsAg), made in yeast. The vaccine contains only this protein, not the viral genome, so nothing in it can replicate and cause infection.
8 Recombinant: insulin from E. coli, hepatitis B vaccine from yeast, growth hormone from bacteria. Not recombinant: penicillin (a natural product of the mould) and pig insulin (extracted). Answer: $3$.
II
Gene therapy, stem cells and molecular diagnosis.
  • 1 Define gene therapy. Why would correcting a gene in an early embryo give a permanent cure while correcting blood cells does not?
  • 2 What is adenosine deaminase, what causes its deficiency, and when and on whom was the first clinical gene therapy performed?
  • 3 Name two treatments for ADA deficiency that were used before gene therapy. Why is neither completely curative?
  • 4 Describe, step by step, the gene therapy given for ADA deficiency. Why must it be repeated?
  • 5 Define a stem cell. Arrange totipotent, multipotent and pluripotent cells in decreasing order of potency, giving one example of each.
  • 6 What ethical objection is raised against embryonic stem cells? How do induced pluripotent stem cells avoid it?
  • 7 Why can PCR detect an infection before any symptom appears? Give three uses of PCR in diagnosis.
  • 8 State the principle of ELISA. Name the two kinds of molecule it can detect to show an infection.
  • 9 200 bacterial clones of a human gene are screened with a radioactive probe complementary to the normal gene. After autoradiography, 197 spots appear on the film. How many clones carry the mutated gene?
1 A collection of methods that corrects a gene defect diagnosed in a child or embryo by delivering a normal gene into the person's cells to take over the function of the non-functional gene. In an early embryo, the corrected cells give rise to all the body's cells (and the germ line), so the correction is permanent; mature blood cells die and are replaced by uncorrected ones.
2 An enzyme crucial for the functioning of the immune system. Its deficiency is caused by the deletion of the gene for ADA. First clinical gene therapy: 1990, a four-year-old girl with ADA deficiency.
3 Bone marrow transplantation, and enzyme replacement therapy (injection of functional ADA). The first is possible only in some children; the second supplies the enzyme but not the gene, so it must be repeated; neither corrects the defect completely.
4 Lymphocytes from the patient's blood are grown in culture outside the body; a functional ADA cDNA is introduced into them using a retroviral vector; the engineered lymphocytes are returned to the patient. Lymphocytes are not immortal, so periodic infusions are needed.
5 An undifferentiated cell that can renew itself and differentiate into specialised cells. Totipotent (zygote) > pluripotent (embryonic stem cells from the inner cell mass) > multipotent (haematopoietic stem cells of bone marrow).
6 Obtaining them destroys an early embryo. iPS cells are made by reprogramming the patient's own adult cells, so no embryo is used (and the cells match the patient).
7 It amplifies the pathogen's nucleic acid, so even a very low concentration of a virus or bacterium — present before symptoms — becomes detectable. Uses: detecting HIV in suspected AIDS patients; detecting mutations in genes of suspected cancer patients; identifying other genetic disorders.
8 Antigen–antibody interaction. It detects either the pathogen's antigens (proteins, glycoproteins) or the antibodies made against the pathogen.
9 The probe hybridises only to the normal sequence, so the mutated clones do not appear: $200-197=3$.
III
GM crops, Bt toxin and RNA interference.
  • 1 Name the three options for increasing food production. Why is the Green Revolution approach not enough on its own?
  • 2 List five ways in which genetic modification has made crop plants more useful.
  • 3 What is Golden rice, and which deficiency is it meant to fight?
  • 4 Name the source of Bt toxin and the three groups of insects killed by different Bt toxins, with one example of each.
  • 5 Explain why Bt toxin does not kill the bacterium that makes it, and describe the steps by which it kills an insect larva.
  • 6 Match: (a) cryIAc (b) cryIAb (c) cryIIAb — with (i) corn borer (ii) cotton bollworm. One item of List-II may be used twice.
  • 7 What is RNA interference? Name two natural sources of the complementary RNA.
  • 8 Describe how nematode-resistant tobacco plants were produced. Name the nematode.
  • 9 Applied (illustrative numbers). A farmer used to spray insecticide 8 times a season on 4 hectares of cotton, at $\text{₹}\,1500$ per hectare per spray. After switching to Bt cotton he needs only 2 sprays (against sucking pests that Bt toxin does not kill). How much does he save on spraying per season?
1 Agro-chemical-based agriculture, organic agriculture, genetically engineered crop-based agriculture. The Green Revolution's gains came mainly from fertilisers and pesticides, which are costly for poor farmers and harm the environment; conventional breeding cannot raise yields of existing varieties much further.
2 Tolerance to abiotic stresses (cold, drought, salt, heat); less reliance on chemical pesticides (pest resistance); fewer post-harvest losses; more efficient use of minerals (soil fertility not exhausted early); better nutritional value.
3 A GM rice enriched in vitamin A (its grain makes β-carotene); it is meant to fight vitamin A deficiency.
4 Bacillus thuringiensis. Lepidopterans (tobacco budworm, armyworm), coleopterans (beetles), dipterans (flies, mosquitoes).
5 It is stored as an inactive protoxin in crystals. In the larva's alkaline gut the crystals dissolve and the protoxin becomes active; the active toxin binds to the surface of midgut epithelial cells and creates pores; the cells swell and lyse, and the insect dies.
6 (a)–(ii), (b)–(i), (c)–(ii).
7 A method of cellular defence in eukaryotes: a specific mRNA is silenced by a complementary dsRNA molecule that binds it and prevents its translation. Sources: infection by viruses with RNA genomes; transposons that replicate via an RNA intermediate.
8 Nematode-specific genes were introduced into tobacco using Agrobacterium vectors so as to produce both sense and anti-sense RNA; these paired into dsRNA, which silenced the specific mRNA of the nematode, so the parasite could not survive in the transgenic plant. The nematode: Meloidogyne incognita (infects tobacco roots).
9 Sprays saved per season: $8-2=6$. Saving $=6\times4\ \text{ha}\times\text{₹}\,1500=\text{₹}\,36\,000$.
IV
Transgenic animals and the ethics of biotechnology.
  • 1 Define a transgenic animal. Which animal makes up over 95 % of existing transgenic animals, and why do you think it is so popular?
  • 2 List the five reasons for producing transgenic animals, with one example for each.
  • 3 Give the year, the human protein and the protein's concentration in the milk of Rosie. Why was the milk useful?
  • 4 Which human disease is treated with α-1-antitrypsin made in transgenic animals?
  • 5 Why could transgenic mice replace monkeys in testing the safety of the polio vaccine?
  • 6 What is the GEAC? State its two functions.
  • 7 Define biopiracy, and explain the Basmati case. Name two other Indian bio-resources that have been the subject of patent attempts.
  • 8 Applied (illustrative numbers). A transgenic goat gives 3 litres of milk a day containing 5 g of a human therapeutic protein per litre. Purification recovers 80 % of it. One patient needs 12 g of the protein per week. How many patients can one goat supply?
1 An animal whose DNA has been manipulated to possess and express an extra (foreign) gene. The mouse: it is small, cheap to keep, breeds fast with short generations, and its genetics are very well known.
2 Normal physiology and development (insulin-like growth factor); study of disease (models for cancer, cystic fibrosis, rheumatoid arthritis, Alzheimer's); biological products (α-1-antitrypsin, Rosie's milk); vaccine safety (polio vaccine in transgenic mice); chemical safety (toxicity testing in animals made more sensitive to toxins).
3 1997; human alpha-lactalbumin, 2.4 g per litre. The milk was nutritionally more balanced for human babies than natural cow milk.
4 Emphysema.
5 Mice carrying the right human genes respond to the vaccine as humans would, and are cheaper and quicker to breed and test than monkeys; if reliable, they could replace monkeys.
6 The Genetic Engineering Approval (now Appraisal) Committee, set up by the Government of India. It decides on the validity of GM research and on the safety of introducing GM organisms for public services.
7 Use of bio-resources by multinational companies and other organisations without proper authorisation from the countries and people concerned, and without compensatory payment. In 1997 an American company obtained a US patent on Basmati rice, a variety derived from Indian farmers' varieties (India has 27 documented Basmati varieties). Turmeric and neem.
8 Protein per day $=3\times5=15$ g; purified $=0.80\times15=12$ g/day $=84$ g/week. Patients $=84/12=7$.
🎯 Exam corner NEET · MCQ

E1. NEET · MCQ Statement I: In the first clinical gene therapy, a functional ADA cDNA was introduced into lymphocytes taken from the patient, using a retroviral vector. Statement II: Because lymphocytes are immortal, a single infusion of the engineered lymphocytes gave the patient a permanent cure. Choose the correct option. (A) Both statements I and II are correct (B) Both statements I and II are incorrect (C) Statement I is correct but statement II is incorrect (D) Statement I is incorrect but statement II is correct

Check Statement I is exactly the 1990 procedure ✓. Lymphocytes are not immortal, so the patient needs periodic infusions; a permanent cure would need the gene in cells at an early embryonic stage ✗.
Answer (C).

E2. NEET · MCQ Assertion (A): The Bt toxin protein does not kill the bacterium Bacillus thuringiensis that produces it. Reason (R): In the bacterium, the toxin is present as an inactive protoxin, which becomes active only in the alkaline gut of an insect. (A) Both A and R are true and R is the correct explanation of A (B) Both A and R are true but R is not the correct explanation of A (C) A is true but R is false (D) A is false but R is true

Reason The bacterium survives precisely because it stores the toxin in an inactive form; only an insect's alkaline gut solubilises the crystals and activates it. R explains A.
Answer (A).

E3. NEET · MCQ Match List-I with List-II. List-I: (a) cryIAb (b) cryIAc (c) human alpha-lactalbumin (d) α-1-antitrypsin. List-II: (i) treatment of emphysema (ii) corn borer (iii) cotton bollworm (iv) milk of the transgenic cow Rosie. (A) a-iii, b-ii, c-iv, d-i (B) a-ii, b-iii, c-i, d-iv (C) a-iv, b-iii, c-ii, d-i (D) a-ii, b-iii, c-iv, d-i

Recall cryIAb — corn borer; cryIAc (with cryIIAb) — cotton bollworms; alpha-lactalbumin — Rosie's milk (1997); α-1-antitrypsin — emphysema.
Answer (D).
⏱ Shortcut "Ab" for the corn borer ("Ab = maize borer") gives a-ii, leaving (B) and (D); Rosie's milk protein is alpha-lactalbumin (c-iv), so (D).

E4. NEET · MCQ How many of the following statements are correct? (i) Golden rice is a vitamin A-enriched rice. (ii) Over 95 % of all existing transgenic animals are mice. (iii) ELISA is based on the principle of antigen–antibody interaction. (iv) The 1997 patent on Basmati rice was granted by the Indian Patent Office. (v) In RNA interference, a complementary double-stranded RNA silences a specific mRNA. (vi) Bt toxin is activated by the acidic pH of the insect's gut. (A) three (B) four (C) five (D) two

Check (i) ✓; (ii) ✓; (iii) ✓; (iv) ✗ — an American company obtained it through the US Patent and Trademark Office; (v) ✓; (vi) ✗ — the gut pH is alkaline.
Answer Four: (B).

E5. NEET · MCQ The diagram shows a molecule made in the β-cells of the pancreas, with four parts labelled P, Q, R and S. Which labelled part is absent from mature insulin, and how many amino acids does chain P contain? PQRS (A) Q; P contains 21 amino acids (B) Q; P contains 30 amino acids (C) R; P contains 21 amino acids (D) S; P contains 30 amino acids

Read the diagram The molecule is proinsulin. The loop Q joining the end of one chain to the start of the other is the C peptide; S are disulphide bridges; the shorter chain P is chain A, the longer chain R is chain B.
Recall The C peptide is removed during maturation; chain A has 21 amino acids (chain B has 30).
Answer (A).

E6. NEET · MCQ Arrange the steps of gene therapy for ADA deficiency in the correct order: (i) lymphocytes are grown in a culture outside the body (ii) blood is taken from the patient (iii) a functional ADA cDNA is introduced into the lymphocytes with a retroviral vector (iv) the engineered lymphocytes are infused into the patient. (A) i, ii, iii, iv (B) ii, iii, i, iv (C) iii, ii, i, iv (D) ii, i, iii, iv

Logic The cells must be taken (ii) before they can be cultured (i); the gene is put into the cultured lymphocytes (iii); only then are they returned (iv). (A) cultures cells not yet taken; (B) and (C) add the gene before the cells are in culture.
Answer (D).
🔬 Research–Teaching NexusResearch-tutored · optional, about 30 minutes

Research question. ELISA and PCR can both diagnose an infection such as HIV. Which one detects an infection sooner, and when a screening test comes back positive, how likely is it that the person is really infected?

Why it matters. Blood banks in Mumbai, Nairobi and Bogotá screen millions of donations a year; clinics must decide whom to treat. An antibody ELISA is cheap and fast but cannot see an infection until the body has made antibodies — the window period. PCR sees the virus's own nucleic acid much earlier but costs more and needs a laboratory. And because infection is rare among donors, even a very accurate test produces many false alarms — which is why a positive screen is always confirmed by a second test.

What to do.

  1. (Illustrative numbers.) After an infection, the virus first appears in the blood on day 3 at 1 copy per mL, and its level doubles every day. A PCR test detects it once it reaches 50 copies per mL. An antibody ELISA becomes positive on day 25. On which day does PCR first detect the infection, and how many days shorter is its window period?
  2. An ELISA kit is tried on 1000 people known to be infected and 1000 known to be uninfected. It is positive for 995 of the infected and negative for 990 of the uninfected. Calculate its sensitivity (the percentage of infected people it detects) and its specificity (the percentage of uninfected people it correctly calls negative).
  3. The kit is used to screen 100 000 blood donors, of whom 0.5 % are infected. How many true positives and how many false positives do you expect? What percentage of the positive results are true (the positive predictive value)?
  4. Explain, from your answers, why a positive screening ELISA is followed by a confirmatory test, and why blood banks in some countries add a nucleic-acid (PCR-type) test.

Tools: a calculator or a spreadsheet; the PCR cycle counter of Section 9.1 for the idea of amplification.

Hand in: a timeline marking the two detection days, your sensitivity, specificity and predictive-value calculations in a table, and a paragraph comparing ELISA and PCR (what each detects, speed, cost, when each is the better choice).

Going further. Find out what a "fourth-generation" HIV test detects (both an antigen and antibodies) and how much it shortens the window period compared with an antibody-only test.

Instructor note (illustrative data): level on day $3+k$ is $2^{k}$ copies/mL; $2^{5}=32\lt50\le2^{6}=64$, so PCR detects on day $9$; window shorter by $25-9=16$ days. Sensitivity $995/1000=99.5\%$; specificity $990/1000=99.0\%$. Screening: $500$ infected, $99\,500$ uninfected; true positives $0.995\times500=497.5\approx498$; false positives $0.010\times99\,500=995$; PPV $=497.5/(497.5+995)=0.333$, about one positive in three is real. Low prevalence makes false positives outnumber true ones even with 99 % specificity, hence confirmation; nucleic-acid testing closes most of the window period, catching donors infected too recently for antibodies.

🧪 Self-check quiz

0/5 correct

Q1. Transgenic tobacco plants were protected by RNA interference against

Q2. The GEAC set up by the Government of India

Q3. A very low concentration of a virus in a patient, before any symptom appears, is best detected by

Q4. Golden rice is a genetically modified rice enriched in

Q5. The first clinical gene therapy, in 1990, was given to treat